Argos Therapeutics to Report Fourth Quarter and Year-End 2017 Financial Results and Operational Highlights on Monday, April ...
March 28 2018 - 5:00PM
Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company
focused on the development and commercialization of individualized
immunotherapies based on the ArcelisĀ® precision immunotherapy
technology platform, today announced that it will report fourth
quarter and year-end 2017 financial results and operational
highlights prior to the market open on Monday, April 2, 2018.
About Argos Therapeutics
Argos Therapeutics is an immuno-oncology company
focused on the development and commercialization of individualized
immunotherapies for the treatment of cancer and infectious diseases
using its ArcelisĀ® technology platform. Argos' most advanced
product candidate, Rocapuldencel-T, is being evaluated in the
pivotal ADAPT Phase 3 clinical trial for the treatment of
metastatic renal cell carcinoma (mRCC). Argos is also developing a
separate ArcelisĀ®-based product candidate, AGS-004, for the
treatment of human immunodeficiency virus (HIV), which is currently
being evaluated in an investigator-initiated Phase 2 clinical trial
aimed at HIV eradication in adult patients. Funding for the
development of AGS-004 has been provided by the National Institutes
of Health, the National Institute of Allergy and Infectious
Diseases, and the Collaboratory of Research for AIDS
Eradication.
Investor Contact: Richard Katz, MD, MBAChief
Financial Officer Argos Therapeutics, Inc. 919-287-6315
rkatz@argostherapeutics.com
Media Contact:Adam DaleyBerry & Company
Public Relations212.253.8881adaley@berrypr.com